SCHEMBL23700613

SCHEMBL23700613

CN(C)C1C2CN(C(=O)OC(C)(C)C)CC21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.49
DDB1 Q16531 1/20 0.44
CRBN Q96SW2 1/20 0.44
USP2 O75604 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HPGD P15428 1/20 0.41
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
KMT2A Q03164 1/20 0.40
JAK3 P52333 1/20 0.40
USP30 Q70CQ3 2/20 0.39
RECQL P46063 1/20 0.39
EPHX1 P07099 1/20 0.39
NAMPT P43490 1/20 0.38
CHRM2 P08172 1/20 0.38
CHRM1 P11229 1/20 0.38
CHRM3 P20309 1/20 0.38
RORC P51449 1/20 0.37
EPHX2 P34913 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23700557 1.00 NR1H2 (0.49) NR1H2DDB1CRBNUSP2SMN1; SMN2
SCHEMBL28506418 1.00 NR1H2 (0.49) NR1H2DDB1CRBNUSP2SMN1; SMN2
SCHEMBL23700614 1.00 NR1H2 (0.49) NR1H2DDB1CRBNUSP2SMN1; SMN2
SCHEMBL23719680 1.00 NR1H2 (0.49) NR1H2DDB1CRBNUSP2SMN1; SMN2
SCHEMBL18082348 0.85 NR1H2 (0.58) NR1H2DDB1CRBNUSP2SMN1; SMN2
SCHEMBL16759817 0.85 NR1H2 (0.58) NR1H2DDB1CRBNUSP2SMN1; SMN2
SCHEMBL3563885 0.81 DDB1 (0.52) NR1H2DDB1CRBNUSP2SMN1; SMN2
SCHEMBL16199693 0.79 NR1H2 (0.53) NR1H2DDB1CRBNUSP2SMN1; SMN2
SCHEMBL22961278 0.79 NR1H2 (0.53) NR1H2DDB1CRBNUSP2SMN1; SMN2
SCHEMBL12142155 0.79 NR1H2 (0.53) NR1H2DDB1CRBNUSP2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3802549-B1 NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION HOFFMANN LA ROCHE (CH) 2023-03-01 EP disclosed
US-20210238197-A1 NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION HOFFMANN-LA ROCHE INC. (US) 2021-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238197-A1 NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION O60361, ARG1, QDPR NR1H2 124/4885DDB1 758/4885CRBN 2575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.